Chiesi’s mission is to become a global leader in neonatology and respiratory diseases. Chiesi has four core therapeutic areas such as respiratory, cardiovascular, musculoskeletal/inflammation and neonatology. Chiesi is also particularly dedicated to the treatment of cystic fibrosis and beta thalassaemia. The company’s main marketed products are Clenil® for asthma, Brexin® and Curosurf®, a lung surfactant for respiratory distress syndrome.